Rheumatoid ArthritisPhase 3NCT00754572
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Phase 3 study testing tocilizumab [RoActemra/Actemra] and methotrexate in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 69 sites in 10 countries.
Trial summary
This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- tocilizumab [RoActemra/Actemra] and methotrexate
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 418 participants
- Where
- 69 sitesin 10 countries
- Study dates
- Feb 2009to Oct 2012
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients >=18 years with moderate to severe active RA for at least 6 months;
- swollen joint count >=6 (66 joint count) and tender joint count >=8 (68 joint count) at screening;
- inadequate response to stable dose of MTX;
- patients of reproductive potential must be using a reliable means of contraception.
Who cannot join
- rheumatic autoimmune disease other than RA;
- patients with functional class IV RA;
- diagnosis of juvenile idiopathic or rheumatoid arthritis before age 16 or a history of current inflammatory joint disease other than RA;
- prior treatment failure with anti-tumor necrosis factor agent;
- pregnant or breastfeeding women.
Trial locations and contacts
69 sites in 10 countries.
69 sites in 10 countries
Brazil22 sites
Study site
Belo Horizonte, Minas Gerais, 30150-221
Study site
Botucatu, São Paulo, 18600-400
Study site
Brasília, Federal District, 70840-901
Study site
Campinas, São Paulo, 13059-900
Study site
Campinas, São Paulo, 13083-888
Study site
Caxias do Sul, Rio Grande do Sul, 95070-560
Study site
Curtiba, Paraná, 80030-110
Study site
Florianópolis, Santa Catarina, 88040-970
Study site
Fortaleza, Ceará, 60170001
Study site
Juiz de Fora, Minas Gerais, 36010-570
Study site
Porto Alegre, Rio Grande do Sul, 90035-003
Study site
Porto Alegre, Rio Grande do Sul, 90610-000
Study site
Recife, Pernambuco, 50000-000
Study site
Ribeirão Preto, São Paulo, 14048-900
Study site
Rio de Janeiro, Rio de Janeiro, 20551-030
Study site
Salvador, Estado de Bahia, 40050-410
Study site
Santo André, São Paulo, 09060-650
Study site
São José do Rio Preto, São Paulo, 15090-000
Study site
São Paulo, São Paulo, 04027-000
Study site
São Paulo, São Paulo, 04039-004
Study site
São Paulo, São Paulo, 04266-010
Study site
Vitória, Espírito Santo, 29043-910
Chile8 sites
Study site
Concepción, 1436
Study site
Santiago, 352
Study site
Santiago, 7500000
Study site
Santiago, 7550000
Study site
Santiago, 8320000
Study site
Santiago, 8380000
Study site
Santiago, 8860000
Study site
Temuco, 4780000
Colombia8 sites
Study site
Barranquilla
Study site
Bogotá, 49 00
Study site
Bogotá
Study site
Bucaramanga, 0
Study site
Cali
Study site
Chia-Cundinamarca
Study site
Medellín, 0
Study site
Medellín
Mexico8 sites
Study site
Chihuahua City, 31238
Study site
Guadalajara, 44650
Study site
Mexico City, 03900
Study site
Mexico City, 11850
Study site
Mexico City, 14140
Study site
Miexico City, 06700
Study site
Querétaro, 76000
Study site
San Luis Potosí City, 78240
Argentina6 sites
Study site
Buenos Aires, C1280AEB
Study site
Buenos Aires, C1425ASQ
Study site
Buenos Aires, C1426AAL
Study site
Córdoba, X5000FAL
Study site
San Miguel, T4000AXL
Study site
San Miguel de Tucumán, T4000IFP
Costa Rica4 sites
Study site
Cartago, 0
Study site
Heredia, 00
Study site
San José, 10103
Study site
San José
Ecuador4 sites
Study site
Cuenca
Study site
Guayaquil
Study site
Quito, EC170517
Study site
Quito
Peru4 sites
Study site
Arequipa, 04001
Study site
Jesus Maria
Study site
Lima, LIMA 14
Study site
San Isidro, Lima 27
Venezuela4 sites
Study site
Barquisimeto, 3005
Study site
Caracas, 1010
Study site
Caracas, 1040
Study site
Maracaibo, 4001
About this study
Official title: A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis
This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Patients will receive tocilizumab 8mg/kg iv, every 4 weeks and methotrexat e 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and th e target sample size is <500 individuals.
- Conditions
- Rheumatoid Arthritis
- Being tested
- tocilizumab [RoActemra/Actemra], methotrexate
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
tocilizumab [RoActemra/Actemra]Drug
8mg/kg iv, every 4 weeks
methotrexateDrug
10-25mg oral or parenteral weekly.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24
ACR50 is defined as 50 percent (%) improvement in: a) Swollen Joints Count (SJC) and Tender Joints Count (TJC) and b) Three of the following 5 assessments:
- Participant's global assessment of pain by Visual Analog Scale (VAS)
- Participant's global assessment of disease activity (VAS)
- Investigator/Physician's global assessment of disease activity (VAS)
- Participant's assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)
- Acute phase reactant levels - Erythrocyte Sedimentation Rate or C-Reactive Protein (ESR or CRP)
Measured: Week 24
Secondary outcomes (23)
Percentage of Participants With ACR20 and ACR70 Response at Week 24
ACR20 and ACR70 are defined as 20 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments:
- Participant's global assessment of pain by VAS
- Participant's global assessment of disease activity (VAS)
- Investigator/Physician's global assessment of disease activity (VAS)
- Participant's assessment of disability measured by HAQ-DI
- Acute phase reactant (ESR or CRP)
Measured: Week 24
Time to Onset of ACR20, ACR50, and ACR70
ACR20, ACR50 and ACR70 are defined as 20, 50 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments:
- Participant's global assessment of pain by VAS
- Participant's global assessment of disease activity (VAS)
- Investigator/Physician's global assessment of disease activity (VAS)
- Participant's assessment of disability measured by HAQ-DI
- Acute phase reactant (ESR or CRP)
Measured: Baseline and Week 24
Change From Baseline in Hemoglobin at Week 24
Measured: Baseline and Week 24
SJC and TJC at Baseline and Week 24
The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).
Measured: Baseline and Week 24
Percent Change From Baseline in SJC and TJC at Week 24
The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).
Measured: Baseline and Week 24
Pain as Assessed by the Participant at Baseline and Week 24
The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.
Measured: Baseline and Week 24
Percent Change From Baseline in Pain as Assessed by the Participant at Week 24
The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.
Measured: Baseline and Week 24
Participant's Global Assessment of Disease Activity at Baseline and Week 24
The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).
Measured: Baseline and Week 24
Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24
The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).
Measured: Baseline and Week 24
Physician's Global Assessment of Disease Activity at Baseline and Week 24
The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).
Measured: Baseline and Week 24
Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24
The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).
Measured: Baseline and Week 24
HAQ-DI at Baseline and Week 24
HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 =without difficulties; 1= with some difficulties; 2=with great difficulties; and 3= unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).
Measured: Baseline and Week 24
Percent Change From Baseline in HAQ-DI at Week 24
HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).
Measured: Baseline and Week 24
Area Under The Curve (AUC) of the ACR(n)
ACR-n was defined as the lowest of 3 values (the percent change in the swollen joint count, the percent change in the tender joint count, and the median of the other 5 measures in the ACR core data set which included Participant's global assessment of pain (VAS), Participant's global assessment of disease activity (VAS), Investigator/Physician's global assessment of disease activity (VAS), Participant's assessment of disability measured by the HAQ-DI Acute phase reactant levels - ESR or CRP). Therefore, a percentage value was assigned to each participant at each timepoint. AUC was calculated for each participant from baseline to Week 112. Mean and standard deviation values are are provided in percent*years.
Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving ACR20 Response
ACR20 is defined as 20% improvement in: a) SJC and TJC and b) Three of the following 5 assessments:
- Participant's global assessment of pain (VAS)
- Participant's global assessment of disease activity (VAS)
- Investigator/Physician's global assessment of disease activity (VAS)
- Participant's assessment of disability measured by the HAQ-DI
- Acute phase reactant levels - ESR or CRP
Measured: Week 2
Odds Estimates for ACR Positive Response in Generalized Estimating Equation (GEE) Models
The probability of ACR positive response was determined using the GEE.
Measured: Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24
DAS28 calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) >3.2 to 5.1 = moderate to high disease activity.
Measured: Baseline and Week 24
Percentage of Participants With a Response by Categorical DAS28 Responses According to The European League Against Rheumatism (EULAR Response) at Week 24
DAS28- based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline >1.2 with DAS28 < 3.2; moderate response: change from baseline >1.2 with DAS28 >3.2 to <5.1 or change from baseline >0.6 to <1.2 with DAS28 <5.1; No response: change from baseline < 0.6 or change from baseline >0.6 and <1.2 with DAS28 >5.1.
Measured: Week 24
AUC of DAS28
The AUC was computed using the trapezoidal rule, considering baseline value as 0, through NCSS software. For each participant, AUC for DAS28 units was calculated. Each individual AUC DAS28 value was divided by 52 to have the conversion of AUC DAS28 in unit weeks to AUC DAS28 in unit years, as 1 week is approximately 1/52 years. The set of individual AUC DAS28 was computed as summary statistics.
Measured: Weeks 2, 4, 8, 12, 16, 20 and 24
Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.
Measured: Week 24
Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24
DAS28 calculated from the SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) >3.2 to 5.1 = moderate to high disease activity and DAS28<2.6 = remission
Measured: Week 24
Quality of Life (QoL) Assessed by Short-Form 36 (SF-36) at Week 24
SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. Total of 3 variables were analyzed (2 composite subscales and vitality score). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Week 24
Mean Change in Rheumatoid Factor (RF) at Week 24 in Participants With Positive RF
Measured: Baseline and Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2008 (estimated)
- Study startFeb 2009
- Primary completionOct 2012
- Study completionOct 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 418 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00754572
- Sponsor's protocol ID
- ML21530
- Status last verified
- May 2015
- First submitted
- 17 Sep 2008
- Last updated
- 15 May 2015
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis
- ClinicalTrials.gov ID
- NCT00754572
- Acronym / sponsor ID
- ML21530
- Conditions
- Rheumatoid Arthritis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 418 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- Feb 2009
- Primary completion
- Oct 2012 (actual)
- Study completion
- Oct 2012 (actual)
- First posted
- 18 Sep 2008 (estimated)
- Results
- Posted 15 May 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Patients will receive tocilizumab 8mg/kg iv, every 4 weeks and methotrexat e 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and th e target sample size is <500 individuals.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: tocilizumab [RoActemra/Actemra], Drug: methotrexate |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- patients >=18 years with moderate to severe active RA for at least 6 months;
- swollen joint count >=6 (66 joint count) and tender joint count >=8 (68 joint count) at screening;
- inadequate response to stable dose of MTX;
- patients of reproductive potential must be using a reliable means of contraception.
Key exclusion criteria (5 listed)
- rheumatic autoimmune disease other than RA;
- patients with functional class IV RA;
- diagnosis of juvenile idiopathic or rheumatoid arthritis before age 16 or a history of current inflammatory joint disease other than RA;
- prior treatment failure with anti-tumor necrosis factor agent;
- pregnant or breastfeeding women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| tocilizumab [RoActemra/Actemra]8mg/kg iv, every 4 weeks | Drug | 1 |
| methotrexate10-25mg oral or parenteral weekly. | Drug | 1 |
Primary outcome
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24
Time frame: Week 24
ACR50 is defined as 50 percent (%) improvement in: a) Swollen Joints Count (SJC) and Tender Joints Count (TJC) and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by Visual Analog Scale (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) 5. Acute phase reactant levels - Erythrocyte Sedimentation Rate or C-Reactive Protein (ESR or CRP)
23 secondary outcomes
Percentage of Participants With ACR20 and ACR70 Response at Week 24
Time frame: Week 24
Time to Onset of ACR20, ACR50, and ACR70
Time frame: Baseline and Week 24
Change From Baseline in Hemoglobin at Week 24
Time frame: Baseline and Week 24
SJC and TJC at Baseline and Week 24
Time frame: Baseline and Week 24
Percent Change From Baseline in SJC and TJC at Week 24
Time frame: Baseline and Week 24
Pain as Assessed by the Participant at Baseline and Week 24
Time frame: Baseline and Week 24
Percent Change From Baseline in Pain as Assessed by the Participant at Week 24
Time frame: Baseline and Week 24
Participant's Global Assessment of Disease Activity at Baseline and Week 24
Time frame: Baseline and Week 24
Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24
Time frame: Baseline and Week 24
Physician's Global Assessment of Disease Activity at Baseline and Week 24
Time frame: Baseline and Week 24
Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24
Time frame: Baseline and Week 24
HAQ-DI at Baseline and Week 24
Time frame: Baseline and Week 24
Percent Change From Baseline in HAQ-DI at Week 24
Time frame: Baseline and Week 24
Area Under The Curve (AUC) of the ACR(n)
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving ACR20 Response
Time frame: Week 2
Odds Estimates for ACR Positive Response in Generalized Estimating Equation (GEE) Models
Time frame: Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24
Time frame: Baseline and Week 24
Percentage of Participants With a Response by Categorical DAS28 Responses According to The European League Against Rheumatism (EULAR Response) at Week 24
Time frame: Week 24
AUC of DAS28
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24
Time frame: Week 24
Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24
Time frame: Week 24
Quality of Life (QoL) Assessed by Short-Form 36 (SF-36) at Week 24
Time frame: Week 24
Mean Change in Rheumatoid Factor (RF) at Week 24 in Participants With Positive RF
Time frame: Baseline and Week 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
69 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing tocilizumab [RoActemra/Actemra] and methotrexate in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 69 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 69 sites in Brazil, Chile, Colombia, Mexico, Argentina and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 May 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24 (time frame: Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2015.